HOSSAM M. HASSAN | Pharmaceutical Sciences | Best Researcher Award

Prof. Dr. HOSSAM M. HASSAN | Pharmaceutical Sciences | Best Researcher Award

prof.Dr. Hossam M. Hassan , College of Pharmacy, University of Kut,Iraq

Dr. Hossam Mokhtar Hassan 🇪🇬 is an esteemed Associate Professor of Pharmacognosy at Nahda University and Beni-Suef University, Egypt 🧪. With a Ph.D. in Pharmaceutical Sciences and postdoctoral training at UCSD’s Scripps Institute 🌊, his expertise lies in natural product chemistry, marine pharmacognosy, and phytotherapy 🌿. He currently serves as Vice-Dean for Postgraduate Affairs and General Manager of the Central Research Lab at NUB 🧫. A dedicated educator and researcher, he has received multiple accolades 🏆 and remains active in scientific societies, pushing the boundaries of drug discovery from natural and marine sources 🔬.

Professional Profile:

Scopus

🎓 Education & Experience 

🎓 Education:

  • 🧪 Ph.D. in Pharmaceutical Sciences, University of Louisiana & Beni-Suef University, 2010

  • 🌿 M.Sc. in Pharmacognosy, Cairo University, 2006

  • 💊 B.Sc. in Pharmaceutical Sciences (Honors), Cairo University, 2000

  • 🌊 Postdoc at Scripps Institute of Oceanography, UCSD, 2013-2014

💼 Experience:

  • 🏛️ Vice-Dean for Postgraduate Affairs, Faculty of Pharmacy, NUB (2019–Present)

  • 👨‍🏫 Associate Professor, Nahda & Beni-Suef Universities (2016–Present)

  • 🧪 General Manager, Central Research Lab, NUB (2017–Present)

📈 Professional Development 

Dr. Hassan has continually honed his skills through international fellowships and academic training 🧳. He has mastered advanced techniques such as NMR, HPLC, LC/MS, GC/MS, and molecular docking for natural product analysis 🔬🧫. His scientific capabilities span pharmacophore modeling, phytochemistry, and marine bioprospecting 🌊🌱. He has also developed leadership skills as a strategic planning team leader at NUB 🗂️, with training in effective teaching, decision-making, communication, and problem-solving 🎯🗣️. His active memberships in the American Society of Pharmacognosy and the Egyptian Syndicate of Pharmacists reflect his commitment to global scientific communities 🌍📚.

🔍 Research Focus Category 

Dr. Hassan’s research is centered on natural product drug discovery, especially from marine and plant-derived sources 🌊🌿. He isolates bioactive compounds from symbiotic bacteria, fungi, and medicinal plants to explore their pharmacological potential 💊. His work involves biotransformation, chemical derivatization, and 3D-QSAR studies for structure–activity relationships 🧪🧬. His expertise in phytochemistry and marine pharmacognosy contributes to identifying novel therapeutic agents against microbial infections, cancer, and fertility disorders 🔬👨‍⚕️. Integrating cutting-edge analytical and modeling techniques, he aims to harness nature’s biodiversity for modern medicine 🌍🧫.

🏆 Awards & Honors 

  • 🏅 Best Master’s Thesis, Faculty of Pharmacy, Cairo University, 2006

  • 🏆 Armor of Excellence, Egyptian Pharmacists Syndicate, 2007

  • 🏆 Armor of Excellence, Egyptian Pharmacists Syndicate, 2012

  • 🎓 Best Ph.D. Thesis in Pharmacognosy, All Egyptian Pharmacy Faculties, 2012

Publication Top Notes:

1. Pachycladins A–E: Eunicellin-Based Diterpenoids

Hassan HM, Khanfar MA, Elnagar AY, Mohammed R, Shaala LA, Youssef DT, Hifnawy MS, El Sayed KA. Pachycladins A–E, prostate cancer invasion and migration inhibitory Eunicellin-based diterpenoids from the Red Sea soft coral Cladiella pachyclados. J Nat Prod. 2010; 73(5):848–853.
https://doi.org/10.1021/np900858m

🔬 Summary:
This study reports the isolation of five new Eunicellin-based diterpenoids, named Pachycladins A–E, from the Red Sea soft coral Cladiella pachyclados. These compounds were shown to inhibit the migration and invasion of prostate cancer cells, indicating promising anticancer potential through marine natural product chemistry.

2. 3D-QSAR of Semisynthetic Eunicellin Diterpenoids

Hassan HM, Elnagar AY, Khanfar MA, Sallam A, Mohammed R, Shaala LA, Youssef DT, Hifnawy MS, El Sayed KA. Design and 3D-quantitative structure-activity relationship of semisynthetic eunicellin-based diterpenoids as prostate cancer migration and invasion inhibitors. Eur J Med Chem. 2011; 46(4):1122–1130.
https://doi.org/10.1016/j.ejmech.2011.01.055

🧪 Summary:
The paper explores the design and synthesis of semisynthetic derivatives of eunicellin-based diterpenoids and develops a 3D-QSAR model to evaluate their anticancer activity. These analogs demonstrated enhanced inhibition of prostate cancer cell migration and invasion, highlighting their potential for further drug development.

3. Semisynthetic Sarcophine Derivatives as Anticancer Agents

Hassan HM, Sallam AA, Mohammed R, Hifnawy MS, Youssef DT, El Sayed KA. Semisynthetic analogues of the marine cembranoid sarcophine as prostate and breast cancer migration inhibitors. Bioorg Med Chem. 2011; 19(16):4928–4934.
https://doi.org/10.1016/j.bmc.2011.06.073

🧬 Summary:
This study details the synthesis of analogues of sarcophine, a marine cembranoid, and evaluates their ability to inhibit migration in prostate and breast cancer cell lines. Several derivatives showed strong bioactivity, offering new leads in anticancer drug discovery.

4. Decorosides A and B: Cytotoxic Flavonoid Glycosides

Mostafa ER, Hossam MH, El-Shaimaa AA, Marcel J, Rainer E. Decorosides A and B, cytotoxic flavonoid glycosides from the leaves of Rhododendron decorum. Nat Prod Commun. 2014; 9(4):473–476.
https://doi.org/10.1177/1934578X1400900408

🌿 Summary:
The article reports the isolation of two new flavonoid glycosides—Decorosides A and B—from Rhododendron decorum. Both compounds exhibited cytotoxic effects, contributing to the growing interest in plant-derived anticancer agents.

5. Salinamide F: A Marine-Derived Depsipeptide Antibiotic

Hossam MH, David D, Kyoung HJ, Richard HE, William F. Salinamide F, new depsipeptide antibiotic and inhibitor of bacterial RNA polymerase from a marine-derived Streptomyces sp. J Antibiot. 2015; 68(3):206–210.
https://doi.org/10.1038/ja.2014.127

🧫 Summary:
This paper describes the discovery of Salinamide F, a novel depsipeptide isolated from Streptomyces sp.. The compound functions as a potent inhibitor of bacterial RNA polymerase, demonstrating promise as a new class of antibiotic against resistant bacteria.

6. Bioactivity of Pulicaria undulata Metabolites

Taha AH, Sayed AE-T, Hossam MH, Mona HH. Cytotoxic and antioxidant activities of secondary metabolites from Pulicaria undulata. Int J Pharm Pharm Sci. 2016; 8(9):150–155.
https://innovareacademics.in/journals/index.php/ijpps/article/view/13208

🌼 Summary:
The study investigates secondary metabolites from Pulicaria undulata, demonstrating both cytotoxic and antioxidant activities. It highlights the plant’s potential as a natural source of therapeutic agents targeting oxidative stress and cancer.

Conclusion:

Prof. Dr. Hossam M. Hassan exemplifies the qualities of a Best Researcher Award recipient through:

  • Innovative scientific contributions in natural products and pharmaceutical chemistry,

  • Strategic academic leadership and international collaboration,

  • Sustained impact on public health-oriented drug discovery.

His work not only advances science but also addresses critical global health challenges such as cancer, antibiotic resistance, and oxidative stress disorders.

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Assist. Prof. Dr. Mohamed skiba | Pharmaceutics Award | Best Innovation Award

Assist. Prof. Dr. Mohamed skiba, University of rouen, France

Dr. Mohamed Skiba, is a French national and a distinguished pharmaceutical scientist. He is a lecturer at the Faculty of Medicine and Pharmacy in Rouen, where he leads the Pharmaceutical Team within the Galenic Group. Dr. Skiba earned his Ph.D. in Pharmaceutical Sciences from the University of Paris XI in 1994 and has been active in pharmaceutical research since 1990, focusing on cyclodextrin and drug vectorization. With over 140 international publications, 80 patents, and numerous contributions to books and congresses, he is a recognized expert in pharmaceutical technology. Dr. Skiba is also an active member of several scientific societies, including the French Society of Chemistry and the French Association of Teachers of Technological Pharmacy. He is fluent in French, English, and Arabic.

Professional Profile:

Orcid

Suitability for Best Innovation Award: Dr. Mohamed SKIBA

Dr. Mohamed Skiba’s extensive work in pharmaceutical sciences, particularly his research in drug formulation and cyclodextrin technologies, positions him as a strong candidate for the Best Innovation Award. His innovations, reflected in his numerous patents and publications, highlight his ability to drive pharmaceutical advancements with real-world applications. His leadership in academic and research institutions further amplifies his impact, making him a deserving recipient of this prestigious award.

🎓Education:

Dr. Mohamed Skiba holds a Ph.D. in Pharmaceutical Sciences, which he earned in 1994 from the University of Paris XI, Southern Paris. His academic journey also includes a Diploma of Thorough Studies in Pharmacotechnology and Biopharmacy (1990) from the University of Paris XI in Châtenay-Malabry. In 1990, he obtained a Diploma in Veterinary Pharmaceuticals from the Faculty of Pharmacy, University of Clermont-Ferrand I. Additionally, Dr. Skiba completed advanced studies in pharmacology and electrophysiology with a Control of Research degree from the University of Poitiers in 1989. He also pursued studies in patent rights at the Faculty of Orsay, University of Paris-South, enriching his expertise in pharmaceutical and intellectual property matters.

🏢Work Experience:

Dr. Mohamed Skiba has been a lecturer at the Faculty of Medicine and Pharmacy, University of Rouen, France, since 1998. In this role, he teaches courses in galenic and industrial galenic pharmacy to both undergraduate and graduate students, while also leading the Pharmaceutical Team within the Galenic Group. His professional experience includes serving as a trainee at the Central Pharmacy of the Hospitals of Paris (PCH) and working as an Associated Attaché in Toxicology and Clinical Pharmacology at the Hospital of Corbeil-Essonnes, further enhancing his expertise in pharmaceutical technology and clinical applications.

🏅Awards & Recognition:

Dr. Mohamed Skiba is a prolific contributor to the field of pharmaceutical technology, holding over 80 patents that highlight his innovative work. He has authored 140 international publications and contributed to 9 book chapters, making significant scholarly impacts. Additionally, Dr. Skiba has presented 71 communications at prestigious scientific congresses, sharing his research and advancements with the global scientific community.

🔬Research Focus:

Dr. Skiba’s research primarily centers on pharmaceutical technology, with a particular focus on cyclodextrin and drug vectorization. His work involves improving drug delivery systems, studying bio-polymeric materials, and developing innovative pharmaceutical formulations. He has been involved in numerous pharmaceutical research projects since 1990, contributing to the advancement of drug delivery and formulation technologies.

Publication Top Notes:

  • Powder Self-Emulsifying Drug Delivery System for Mitotane: In Vitro and In Vivo Evaluation
  • In vitro dissolution of encapsulated or dispersed vitamin E and cholesterol is correlated with preservation of refrigerated ovine sperm
  • Exploring the Therapeutic Potential of Algerian Propolis: GC/MS Profiling, Protective Inclusion Complex, and In Silico Evaluation Against SARS‐CoV‐2 Main Proteases
  • Development of a Novel Cyclodextrin–Chitosan Polymer for an Efficient Removal of Pharmaceutical Contaminants in Aqueous Solution

 

 

Dr. Angela Fabiano | Pharmaceutics Awards | Best Researcher Award

Dr. Angela Fabiano | Pharmaceutics Awards | Best Researcher Award

Dr. Angela Fabiano,University of Pisa,Italy

Angela Fabiano is a senior researcher at the University of Pisa, Department of Pharmacy, specializing in drug delivery systems. She earned her Ph.D. in Science of Drugs and Bioactive Substances in 2016, with a focus on innovative pharmaceutical systems based on chitosan and its derivatives. Her research involves the synthesis, purification, and characterization of chitosan derivatives to enhance solubility and pharmaceutical applications, including nanosystems and hydrogels for drug delivery via ocular and oral routes. In 2020, she achieved the scientific qualification for associate professor and has authored over 30 publications, with around 800 citations.

Professional Profile:

Orcid

Scopus

Suitability for Best Researcher Award:

Angela Fabiano’s innovative research in drug delivery systems, significant academic contributions, and recognized scientific qualifications make her an outstanding candidate for the Best Researcher Award. Her work directly impacts the development of novel pharmaceutical systems, positioning her as a leader in her field.

🎓Education:

Angela Fabiano earned her Ph.D. in Science of Drugs and Bioactive Substances from the University of Pisa in 2016. Her doctoral thesis, titled “Innovative Pharmaceutical Systems Based on Chitosan and Its Derivatives,” focused on developing novel pharmaceutical systems using chitosan and its derivatives. Her research explored the synthesis, purification, and characterization of these derivatives to improve solubility and expand their pharmaceutical applications, particularly in the creation of advanced drug delivery systems. This work laid the foundation for her continued contributions to drug delivery research.

🏢Work Experience:

Angela Fabiano is currently a Senior Researcher at the Department of Pharmacy, University of Pisa. Her research focuses on drug delivery systems, specifically the synthesis, purification, and characterization of chitosan derivatives. She is dedicated to advancing the development of nanosystems and hydrogels for drug delivery through various routes, including ocular and oral. Her work aims to enhance the effectiveness and versatility of pharmaceutical applications, contributing significantly to the field of drug delivery.

🏅Awards & Achievements:

Angela Fabiano is currently a Senior Researcher at the Department of Pharmacy, University of Pisa. Her research focuses on drug delivery systems, including the synthesis, purification, and characterization of chitosan derivatives. She is also involved in the development of advanced nanosystems and hydrogels for drug delivery through ocular and oral routes. In 2020, she achieved scientific qualification for the role of Associate Professor at the University of Pisa. She has authored over 30 publications in journals with medium to high impact factors, and her work has been cited approximately 800 times, underscoring her significant contributions to the field.

Publication Top Notes:

  • Title: Cross-Linked Thiolated Hydroxypropyl-β-Cyclodextrin for Pulmonary Drug Delivery
  • Title: Olive Leaf Extracts from Three Italian Olive Cultivars Exposed to Drought Stress Differentially Protect Cells against Oxidative Stress
  • Title: Betaine- and L-Carnitine-Based Ionic Liquids as Solubilising and Stabilising Agents for the Formulation of Antimicrobial Eye Drops Containing Diacerein
  • Title: Bergamot Essential Oil: A Method for Introducing It in Solid Dosage Forms
  • Title: Thiolated Hydroxypropyl-β-Cyclodextrin: A Potential Multifunctional Excipient for Ocular Drug Delivery